Mediolanum International Funds Ltd Sells 124,019 Shares of IQVIA Holdings Inc. (NYSE:IQV)

Mediolanum International Funds Ltd trimmed its stake in shares of IQVIA Holdings Inc. (NYSE:IQV) by 65.0% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 66,787 shares of the medical research company’s stock after selling 124,019 shares during the quarter. Mediolanum International Funds Ltd’s holdings in IQVIA were worth $13,155,000 as of its most recent SEC filing.

Other institutional investors have also added to or reduced their stakes in the company. Capital Performance Advisors LLP purchased a new stake in shares of IQVIA in the third quarter worth about $27,000. Park Place Capital Corp purchased a new position in shares of IQVIA during the 3rd quarter valued at $28,000. Avior Wealth Management LLC raised its position in shares of IQVIA by 117.6% in the third quarter. Avior Wealth Management LLC now owns 161 shares of the medical research company’s stock worth $38,000 after buying an additional 87 shares in the last quarter. Synergy Asset Management LLC bought a new stake in IQVIA during the fourth quarter valued at $33,000. Finally, Assetmark Inc. grew its position in IQVIA by 612.5% during the third quarter. Assetmark Inc. now owns 228 shares of the medical research company’s stock worth $54,000 after buying an additional 196 shares in the last quarter. Hedge funds and other institutional investors own 89.62% of the company’s stock.

IQVIA Stock Performance

Shares of IQV stock opened at $201.34 on Friday. The company has a quick ratio of 0.81, a current ratio of 0.81 and a debt-to-equity ratio of 1.76. The stock has a fifty day moving average of $200.42 and a 200 day moving average of $220.65. The firm has a market capitalization of $36.54 billion, a price-to-earnings ratio of 26.42, a PEG ratio of 2.12 and a beta of 1.48. IQVIA Holdings Inc. has a 52 week low of $187.62 and a 52 week high of $261.73.

Wall Street Analysts Forecast Growth

IQV has been the topic of several recent analyst reports. Morgan Stanley lowered their price target on IQVIA from $280.00 to $265.00 and set an “overweight” rating on the stock in a report on Monday, November 4th. Barclays dropped their target price on shares of IQVIA from $260.00 to $255.00 and set an “overweight” rating for the company in a research report on Friday, November 1st. Deutsche Bank Aktiengesellschaft lowered their price objective on shares of IQVIA from $270.00 to $265.00 and set a “buy” rating on the stock in a research report on Friday, November 1st. BTIG Research cut their target price on shares of IQVIA from $290.00 to $260.00 and set a “buy” rating for the company in a research report on Friday, November 1st. Finally, JPMorgan Chase & Co. lowered their price target on IQVIA from $279.00 to $240.00 and set an “overweight” rating on the stock in a research report on Tuesday, November 5th. Four analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $255.71.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.